Bendtsen, M.A.F.; Grimm, D.; Bauer, J.; Wehland, M.; Wise, P.; Magnusson, N.E.; Infanger, M.; Krüger, M.
Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma. Int. J. Mol. Sci. 2017, 18, 1736.
https://doi.org/10.3390/ijms18081736
AMA Style
Bendtsen MAF, Grimm D, Bauer J, Wehland M, Wise P, Magnusson NE, Infanger M, Krüger M.
Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma. International Journal of Molecular Sciences. 2017; 18(8):1736.
https://doi.org/10.3390/ijms18081736
Chicago/Turabian Style
Bendtsen, Mathias Alrø Fichtner, Daniela Grimm, Johann Bauer, Markus Wehland, Petra Wise, Nils E. Magnusson, Manfred Infanger, and Marcus Krüger.
2017. "Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma" International Journal of Molecular Sciences 18, no. 8: 1736.
https://doi.org/10.3390/ijms18081736
APA Style
Bendtsen, M. A. F., Grimm, D., Bauer, J., Wehland, M., Wise, P., Magnusson, N. E., Infanger, M., & Krüger, M.
(2017). Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma. International Journal of Molecular Sciences, 18(8), 1736.
https://doi.org/10.3390/ijms18081736